These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

176 related articles for article (PubMed ID: 22890797)

  • 61. Secretory phospholipase A2 mediates progression of acute liver injury in the absence of sufficient cyclooxygenase-2.
    Bhave VS; Donthamsetty S; Latendresse JR; Muskhelishvili L; Mehendale HM
    Toxicol Appl Pharmacol; 2008 Apr; 228(2):225-38. PubMed ID: 18329682
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Transferrin and octaarginine modified dual-functional liposomes with improved cancer cell targeting and enhanced intracellular delivery for the treatment of ovarian cancer.
    Deshpande P; Jhaveri A; Pattni B; Biswas S; Torchilin V
    Drug Deliv; 2018 Nov; 25(1):517-532. PubMed ID: 29433357
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Co-delivery of epirubicin and paclitaxel using an estrone-targeted PEGylated liposomal nanoparticle for breast cancer.
    Tang H; Chen J; Wang L; Li Q; Yang Y; Lv Z; Bao H; Li Y; Luan X; Li Y; Ren Z; Zhou X; Cong D; Liu Z; Jia J; Chen H; Zhao W; Meng Q; Sun F; Pei J
    Int J Pharm; 2020 Jan; 573():118806. PubMed ID: 31678519
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Targeting of stealth liposomes to erbB-2 (Her/2) receptor: in vitro and in vivo studies.
    Goren D; Horowitz AT; Zalipsky S; Woodle MC; Yarden Y; Gabizon A
    Br J Cancer; 1996 Dec; 74(11):1749-56. PubMed ID: 8956788
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Co-delivery of Docetaxel and Resveratrol by liposomes synergistically boosts antitumor efficiency against prostate cancer.
    Zhang L; Lin Z; Chen Y; Gao D; Wang P; Lin Y; Wang Y; Wang F; Han Y; Yuan H
    Eur J Pharm Sci; 2022 Jul; 174():106199. PubMed ID: 35533965
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Emerging roles of secreted phospholipase A(2) enzymes: an update.
    Murakami M; Lambeau G
    Biochimie; 2013 Jan; 95(1):43-50. PubMed ID: 23022039
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Combination of Quercetin and 2-Methoxyestradiol Enhances Inhibition of Human Prostate Cancer LNCaP and PC-3 Cells Xenograft Tumor Growth.
    Yang F; Song L; Wang H; Wang J; Xu Z; Xing N
    PLoS One; 2015; 10(5):e0128277. PubMed ID: 26011145
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Differential expression of sPLA2 following spinal cord injury and a functional role for sPLA2-IIA in mediating oligodendrocyte death.
    Titsworth WL; Cheng X; Ke Y; Deng L; Burckardt KA; Pendleton C; Liu NK; Shao H; Cao QL; Xu XM
    Glia; 2009 Nov; 57(14):1521-37. PubMed ID: 19306380
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Effect of repetitive administration of Doxorubicin-containing liposomes on plasma pharmacokinetics and drug biodistribution in a rat brain tumor model.
    Arnold RD; Mager DE; Slack JE; Straubinger RM
    Clin Cancer Res; 2005 Dec; 11(24 Pt 1):8856-65. PubMed ID: 16361575
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Integrated lipidomics in the secreted phospholipase A(2) biology.
    Murakami M; Sato H; Taketomi Y; Yamamoto K
    Int J Mol Sci; 2011; 12(3):1474-95. PubMed ID: 21673902
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Tumor targeting using anti-her2 immunoliposomes.
    Park JW; Kirpotin DB; Hong K; Shalaby R; Shao Y; Nielsen UB; Marks JD; Papahadjopoulos D; Benz CC
    J Control Release; 2001 Jul; 74(1-3):95-113. PubMed ID: 11489487
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Enhanced therapeutic effects of doxorubicin and paclitaxel in combination with liposome-entrapped ends-modified raf antisense oligonucleotide against human prostate, lung and breast tumor models.
    Mewani RR; Tang W; Rahman A; Dritschilo A; Ahmad I; Kasid UN; Gokhale PC
    Int J Oncol; 2004 May; 24(5):1181-8. PubMed ID: 15067340
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Doxorubicin-conjugated PEGylated dendrimers show similar tumoricidal activity but lower systemic toxicity when compared to PEGylated liposome and solution formulations in mouse and rat tumor models.
    Kaminskas LM; McLeod VM; Kelly BD; Cullinane C; Sberna G; Williamson M; Boyd BJ; Owen DJ; Porter CJ
    Mol Pharm; 2012 Mar; 9(3):422-32. PubMed ID: 22233281
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Estrone-targeted PEGylated Liposomal Nanoparticles for Cisplatin (DDP) Delivery in Cervical Cancer.
    Li Q; Zhu M; Li Y; Tang H; Wang Z; Zhang Y; Xie Y; Lv Z; Bao H; Li Y; Liu R; Shen Y; Zheng Y; Miao D; Guo X; Pei J
    Eur J Pharm Sci; 2022 Jul; 174():106187. PubMed ID: 35430381
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Encapsulation, controlled release, and antitumor efficacy of cisplatin delivered in liposomes composed of sterol-modified phospholipids.
    Kieler-Ferguson HM; Chan D; Sockolosky J; Finney L; Maxey E; Vogt S; Szoka FC
    Eur J Pharm Sci; 2017 May; 103():85-93. PubMed ID: 28263913
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Targeted treatment of choroidal neovascularization using integrin-mediated sterically stabilized liposomes loaded with combretastatin A4.
    Ma L; Liu YL; Ma ZZ; Dou HL; Xu JH; Wang JC; Zhang X; Zhang Q
    J Ocul Pharmacol Ther; 2009 Jun; 25(3):195-200. PubMed ID: 19456253
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Improved tumor-targeting drug delivery and therapeutic efficacy by cationic liposome modified with truncated bFGF peptide.
    Chen X; Wang X; Wang Y; Yang L; Hu J; Xiao W; Fu A; Cai L; Li X; Ye X; Liu Y; Wu W; Shao X; Mao Y; Wei Y; Chen L
    J Control Release; 2010 Jul; 145(1):17-25. PubMed ID: 20307599
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Phospholipase A(2)-susceptible liposomes of anticancer double lipid-prodrugs.
    Arouri A; Mouritsen OG
    Eur J Pharm Sci; 2012 Mar; 45(4):408-20. PubMed ID: 21946258
    [TBL] [Abstract][Full Text] [Related]  

  • 79. 2-Oxoamide inhibitors of phospholipase A2 activity and cellular arachidonate release based on dipeptides and pseudodipeptides.
    Barbayianni E; Stephens D; Grkovich A; Magrioti V; Hsu YH; Dolatzas P; Kalogiannidis D; Dennis EA; Kokotos G
    Bioorg Med Chem; 2009 Jul; 17(13):4833-43. PubMed ID: 19443224
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Synthesis of new secretory phospholipase A2-inhibitory indole containing isoxazole derivatives as anti-inflammatory and anticancer agents.
    Pedada SR; Yarla NS; Tambade PJ; Dhananjaya BL; Bishayee A; Arunasree KM; Philip GH; Dharmapuri G; Aliev G; Putta S; Rangaiah G
    Eur J Med Chem; 2016 Apr; 112():289-297. PubMed ID: 26907155
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.